Frequently Asked Questions About Wegovy in New Zealand

Wegovy is approved for adults with a body mass index (BMI) of 30 kg/m² or higher, or 27 kg/m² or higher with at least one weight-related comorbid condition. Qualifying comorbidities include type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease. Patients must be 18 years or older, as pediatric use has not been approved in New Zealand despite FDA approval for ages 12+ in the United States. Contraindications include pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, previous serious hypersensitivity to semaglutide, and diabetic ketoacidosis. Your healthcare provider will assess your complete medical history, current medications, and weight loss goals to determine if Wegovy is appropriate for your situation.

Most patients begin noticing appetite suppression and modest weight loss within 4-8 weeks of starting Wegovy, though initial doses are intentionally low for tolerability. Clinically meaningful weight loss (≥5% of body weight) typically occurs by weeks 12-16 as doses increase toward the maintenance level of 2.4mg. Maximum weight loss generally occurs between months 6-12, with the STEP trials showing peak effects at 60-68 weeks. A 2023 analysis published in Obesity journal found that patients who lost at least 5% of their body weight by week 16 were significantly more likely to achieve ≥10% weight loss by one year. If you have not achieved at least 5% weight loss by month 4-5 despite good adherence, your provider may reassess whether continuing treatment is appropriate. Weight loss velocity varies considerably between individuals based on baseline weight, metabolic factors, dietary adherence, and physical activity levels.

Wegovy is not currently funded by PHARMAC, New Zealand's pharmaceutical management agency, meaning it is not available through the public health system at subsidized rates. Patients must obtain Wegovy through private prescription and pay full cost out-of-pocket, typically NZD $450-550 monthly. PHARMAC funding decisions consider clinical effectiveness, cost-effectiveness, budget impact, and health need, with obesity medications historically receiving low prioritization compared to treatments for acute conditions. While some patients access initial consultations through public hospital weight management clinics, the medication itself must be purchased privately. Advocacy groups have petitioned PHARMAC to reconsider funding for obesity medications given the substantial health burden and associated costs of obesity-related complications. Until funding status changes, private payment remains the only access pathway for most New Zealand residents seeking Wegovy treatment.

If you miss a Wegovy dose and fewer than 5 days have passed since the scheduled injection, take the missed dose as soon as you remember, then resume your normal weekly schedule. If more than 5 days have passed since the missed dose, skip it entirely and take your next dose on the regularly scheduled day. Do not take two doses within 48 hours of each other, as this increases the risk of severe gastrointestinal side effects and hypoglycemia. If you miss two or more consecutive doses (14+ days), contact your healthcare provider before resuming treatment, as you may need to restart at a lower dose to rebuild tolerance. Missing occasional doses may slow weight loss progress but does not cause dangerous withdrawal effects. Set phone reminders, use a medication tracking app, or establish a consistent weekly routine (such as Sunday mornings) to improve adherence. Studies show that patients who maintain ≥80% adherence achieve significantly better weight loss outcomes than those with irregular dosing patterns.

Most private health insurance policies in New Zealand do not cover Wegovy or other weight loss medications as a standard benefit. Southern Cross Health Society, NIB, Accuro, and other major insurers typically exclude obesity treatments from coverage unless prescribed specifically for type 2 diabetes management with documented medical necessity. Some comprehensive policies may provide partial reimbursement for specialist consultations with endocrinologists or bariatric physicians, but the medication cost itself remains patient responsibility. A small number of employer-sponsored health plans or executive-level policies include weight management benefits, but these are exceptions rather than the norm. Before starting treatment, request a written coverage determination from your insurer with the specific diagnostic codes and medication details. Some telehealth providers offer payment plans that spread costs over multiple months, though total expenditure remains unchanged. The lack of insurance coverage represents a significant access barrier, with treatment costs exceeding NZD $6,000 annually for most patients.

Yes, Wegovy is safe and effective for people with type 2 diabetes, though dosing considerations differ from those without diabetes. The STEP 2 trial specifically evaluated semaglutide 2.4mg in participants with type 2 diabetes, demonstrating mean weight loss of 9.6% compared to 3.4% with placebo at 68 weeks. Beyond weight reduction, participants experienced HbA1c reductions of 1.6% from baseline levels averaging 8.1%. Patients taking insulin or sulfonylureas may require dose adjustments to prevent hypoglycemia, as Wegovy enhances insulin secretion and improves insulin sensitivity. Your diabetes medication regimen should be reviewed before starting Wegovy, with potential reductions in insulin doses of 20-30% or discontinuation of sulfonylureas in some cases. Blood glucose monitoring frequency may need to increase during the initial titration period. Some patients already taking Ozempic (semaglutide 1mg for diabetes) may transition to Wegovy for enhanced weight loss effects, though this requires careful coordination with your prescriber to avoid duplication and manage the dose transition appropriately.